Novel actions of beta-adrenoceptor antagonists: implications for the treatment of cardiac failure

β-肾上腺素受体拮抗剂的新作用：对心力衰竭治疗的影响

• 批准号: nhmrc : 491190
• 负责人: Dr Bronwyn Evans
• 金额: $ 9.51万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2008
• 资助国家: 澳大利亚
• 起止时间: 2008-01-01 至 2008-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/novel-actions-beta-cardiac-failure/77747
• 关键词: Novel; actions; beta; adrenoceptor; antagonists

Almost 2-3 of drugs on the market act on G protein-coupled receptors, and many are antagonists that block receptors. Antagonists were seen as inert compounds that prevent access of natural neurotransmitters or hormones, but recent studies indicate distinct actions. We believe that atypical effects of beta-adrenergic antagonists may explain their usefulness in treating cardiac failure. We seek to understand the process and develop assays to aid the development of new drugs for cardiac failure.

市场上几乎有 2-3 种药物作用于 G 蛋白偶联受体，其中许多是阻断受体的拮抗剂。拮抗剂被视为惰性化合物，可阻止天然神经递质或激素的进入，但最近的研究表明其具有不同的作用。我们相信β-肾上腺素能拮抗剂的非典型作用可以解释它们在治疗心力衰竭方面的作用。我们寻求了解这一过程并开发检测方法，以帮助开发治疗心力衰竭的新药。